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The epigenetic marks located throughout the genome exhibit great variation between normal and transformed cancer cells. While
normal cells contain hypomethylated CpG islands near gene promoters and hypermethylated repetitive DNA, the opposite pattern
is observed in cancer cells. Recently, it has been reported that alteration in the microenvironment of melanocyte cells, such as
substrate adhesion blockade, results in the selection of anoikis-resistant cells, which have tumorigenic characteristics. Melanoma
cells obtained through thismodel show an altered epigenetic pattern, which represents one of the first events during themelanocytes
malignant transformation. BecausemicroRNAs are involved in controlling components of the epigenetic machinery, the aim of this
work was to evaluate the potential association between the expression of miR-203, miR-26, and miR-29 family members and the
genes Dnmt3a, Dnmt3b, Mecp2, and Ezh2 during cells transformation. Our results show that microRNAs and their validated or
predicted targets are inversely expressed, indicating that these molecules are involved in epigenetic reprogramming. We also show
that miR-203 downregulates Dnmt3b in mouse melanocyte cells. In addition, treatment with 5-aza-CdR promotes the expression
of miR-26 and miR-29 in a nonmetastatic melanoma cell line. Considering the occurrence of CpG islands near the miR-26 and
miR-29 promoters, these data suggest that they might be epigenetically regulated in cancer.
1. Introduction
Epigenetic modifications play a pivotal role in modulating
gene expression during development and tissue differenti-
ation, in the establishment and maintenance of genomic
imprinting, and in X chromosome inactivation in female
mammals. The most commonly studied type of epigenetic
modification is the DNA methylation of CpG dinucleotides.
In normal human cells DNA methylation typically occurs
throughout the genome and at repetitive DNA, preserving
genomic stability and inhibiting unwanted transposon reac-
tivation [1–3]. CpG-rich regions, known as CpG islands [4],
which are localized near 60% of coding gene promoters, are
hypomethylated in normal cells [5]. Only one-tenth of these
CpG islands are methylated in a tissue-specific manner [6].
DNA methylation is regulated through a family of DNA
methyltransferases (Dnmt) comprising 5 members. Three
of these proteins mediate the addition of a methyl group
predominantly to DNA cytosines of CpG dinucleotide
sequences. Dnmt1 is ubiquitously expressed at high levels
in proliferating cells and is involved in the maintenance of
DNA methylation. Dnmt3a and Dnmt3b promote de novo
DNA methylation and are highly expressed at the early
stages of development and also in embryonic stem cells
Hindawi Publishing Corporation
BioMed Research International
Volume 2015, Article ID 634749, 11 pages
http://dx.doi.org/10.1155/2015/634749
2 BioMed Research International
(ESC). Immediately after differentiation, both proteins are
downregulated and then remain ubiquitously expressed at
low levels in somatic cells [7].
Posttranslational histone modifications are also involved
in gene regulation, as the acetylation, methylation, or phos-
phorylation of histones can influence their affinity for DNA.
Depending on the specific combination of these marks, they
can either facilitate (e.g., histone 3 lysine 4 trimethylation,
H3K4me3; histone 3 lysine 9 acetylation, H3K9ac) or impede
(e.g., H3K9me3; H3K27me3) the binding of transcriptional
factors to promoter regions [8–10]. DNA methylation and
histonemodifications are associated throughmethyl-binding
proteins (MBP). The best-known MBP, Mecp2, contains two
domains: one that specifically recognizes methylated DNA, a
methyl-binding domain (MBD) [11]; and another that binds
to Sin3 recruiting histone deacetylases, a transcriptional
repression domain (TRD) [12–14] promoting gene silencing.
Despite being ubiquitously expressed throughout all human
tissues,MECP2 is highly expressed in the brain [15].
Contrasting observations have been made in tumor cells,
where repetitive DNA is globally demethylated, promoting
genomic instability [16–18], and oncogene promoters are
less frequently methylated, leading to aberrant expression
[19]. However, a myriad of methylated CpG islands near
promoters, many of which found in tumor suppressor genes
[20], have been observed in cancer cells [21], and the
hypermethylation profile depends on the tumor type [22–
24]. The pattern of posttranslational histone modifications
is also disrupted in tumor cells and might play an essen-
tial role in tumor initiation [25]. As an evidence of how
important epigenetic alterations are during the early steps of
malignant transformation, a recent study showed thatmurine
melanocyte cells that are resistant to apoptosis induction by
adhesion blockade (anoikis-resistant cells) could be selected
when cultured in agarose-coated plates. The clonal colonies
obtained after sequential cycles through the same process
were reported as tumorigenic when injected in syngeneic
mice [26]. However, when cells were treated with 5-aza-2󸀠-
deoxycytidine, a demethylating agent, before each cycle of
anchorage blockade, the derived cells were not malignantly
transformed. Therefore, this study shows that most epige-
netic modifications occur as primordial and essential events
during the establishment of malignant transformation in this
murine melanoma model, rather than as a consequence of
cell transformation [27]. Since microRNAs (miRNAs) are
predicted to regulate the expression of 60%of all coding genes
[28] including the epigenetic machinery (reviewed in [29]),
they are good candidates for promoting aberrant expression
of epigenetic machinery, contributing to the deregulation of
epigenetic marks during cell transformation.
Here, using this murine melanoma model [26, 27], we
demonstrate that Dnmt3a and Dnmt3b are downregulated in
nonmetastatic (4C3−) and metastatic (4C3+) melanoma cell
lines, concomitant with the overexpression of miR-29b and
miR-29c, which are known Dnmt3a and Dnmt3b regulators
[30]. miR-26a, which targets Ezh2 [31], a histone methyl-
transferase belonging to the Polycomb family, was found
to be downregulated in a nonmetastatic melanoma cell line
(4C3−) but upregulated in 4C3+. These data are consistent
with the fluctuation of Ezh2 expression during the transition
from a nonmetastatic to a metastatic melanoma phenotype.
Moreover, the members of the miR-26 family potentially
target Mecp2 and Dnmt3bmRNAs, as predicted by several in
silico miRNA target prediction programs, are upregulated in
4C3+ cells, whereasMecp2 andDnmt3bwere downregulated.
Indeed, recent studies have shown that transfection of miR-
26b in breast cancer cells showed diminished expression
of DNMT3B. On the other hand, transfection of miR-26b
antagomiR showed an overexpression of DNMT3B [32], sug-
gesting that this miRNA is involved in DNMT3b regulation.
We have also seen an inverse correlation between this
miR-203 and DNMT3b in nonmetastatic melanoma cells
compared to normal melanocytes.This result is in agreement
with the predicted target of miR-203 and with the findings
of Coleman group that have reported that breast cancer cells
with hypermethylated DNA phenotype have DNMT3b over-
expression and a downregulation ofmiR-203 [32, 33]. In order
to validate Dnmt3b as miR-203 target, we have transfected
cell withmiR-203 expressing vector, which promotesDnmt3b
downregulation. Additionally, miR-203 is also predicted to
target Mecp2, showing an inverse correlation of expression
between normal melanocytes and nonmetastatic melanoma.
Furthermore, to determine whethermiR-26,miR-29 fam-
ily members and miR-203 could be epigenetically regulated,
cells were treated with the hypomethylating agent 5-aza-
deoxycytidine (5-aza-CdR). The results showed increased
expression of all of the studied miRNAs in 4C3− cells,
which might suggest that these miRNAs are epigenetically
regulated and are more susceptible to destabilization during
cell transformation. Taken together, these data suggest that
epigenetic alterations that occur early during malignant
transformationmight be a result from themodulation ofmiR-
26,miR-29, miR-203, and the consequent effects on key genes
involved in the epigenetic machinery.
2. Materials and Methods
2.1. Cell Culture, Treatment with 5-aza-CdR, and Transfec-
tion with miR-203. Nonmetastatic (4C3−) and metastatic
(4C3+) murine melanoma cells were obtained from melan-a
nontumorigenicmelanocytes [34] through repetitive anchor-
age blockade cycles, as described by Oba-Shinjo et al.
[26]. Melan-a, 4C3−, and 4C3+ cells were grown in RPMI
medium, pH 6.9 (Gibco, Carlsbad, CA), supplemented with
5% fetal bovine serum (Vitrocell, Campinas, SP, Brazil)
and 1% penicillin-streptomycin solution (Life Technologies,
Carlsbad, CA) at 37∘C under 5% CO
2
. In addition, phorbol
myristate acetate (PMA, Sigma, St. Louis, MO) was added
at a final concentration of 200 nM to the complete medium
for melan-a cells. The cells were treated with 10𝜇M 5-aza-
deoxycytidine (5-aza-CdR, Sigma, St. Louis, MO) for 48
hours, followed by RNA or total protein extraction.
An aliquot of 3,5 𝜇g of PSilencer 4.1-CMV-Puro plasmid
containing the sequence of mmu-miR-203 or scrambled was
kindly provided by Dr. Candi, Faculty of Medicine, Depart-
ment of Experimental Medicine and Surgery, Rome [35].
They were transfected into cells with Fugene 6 (Promega),
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and culture was maintained in medium with 4 ug/mL pur-
omycin through 14 days in order to select transfected resistant
cells, followed by RNA and total protein extraction.
2.2. Methylation-Sensitive Single-Nucleotide Primer Extension
Assay (Ms-SNuPE). Global methylation status was inferred
by methylation-sensitive single nucleotide primer extension
(Ms-SNuPE) method. As previously described [27], the aver-
age of methylated CpG sites located at two different repetitive
elements (retrovirus-C long terminal repeats, RC-LTR, and
intracisternal A-particle elements, IAPy) was performed.
2.3. Retrotranscription and Quantitative Real-Time PCR.
Total RNA extracted using TRIzol (Life Technologies, Carls-
bad, CA) was treated with DNase I (Promega, Fitchburg,
Wisconsin) and retrotranscribed using the High Capacity
cDNA Reverse Transcription Kit (Life Technologies, Carls-
bad, CA), and the corresponding loop-primer of the miRNA
Assay Kit (Life Technologies, Carlsbad, CA), according to
the manufacturer’s instructions. The reverse transcription
reaction was followed by quantitative real-time PCR (qRT-
PCR) using specific primers included in miRNA Assay kit
(Life Technologies, Carlsbad, CA) with TaqMan PCRMaster
Mix (Life Technologies, Carlsbad, CA).
2.4.Western Blotting. Total protein was extracted using RIPA
buffer (150mMNaCl, 1% NP-40, 0.5% sodium deoxycholate,
0.1% SDS, and 50mM Tris, pH 8.0) and protease inhibitors
(1mM PMSF, 10 𝜇g/mL aprotinin, 10 𝜇g/mL leupeptin, and
200𝜇M sodium orthovanadate). The obtained protein con-
centration was evaluated in a spectrophotometer. Denatured
protein was loaded onto an SDS-PAGE gel and subsequently
transferred to a PVDF membrane (Bio-Rad, Hercules, CA).
The membrane was incubated with anti-Dnmt3a (1 : 5000,
Abcam, Cambridge, UK, #ab13887); anti-Dnmt3b (1 : 800,
Santa Cruz Biotechnology, Santa Cruz, CA, #sc-70984); anti-
Mecp2 (1 : 1,000, Calbiochem-Merck, Darmstadt, Germany,
#472520); or anti-Ezh2 (1 : 2000, Abcam, Cambridge, UK,
#ab3748) antibodies. For normalization, the membrane was
also incubated with an anti-𝛽-actin antibody (1 : 5,000, Santa
Cruz Biotechnology, Santa Cruz, CA, #sc-101017). Subse-
quently, the membrane was incubated with an anti-mouse or
anti-rabbit secondary antibody (Life Technologies, Carlsbad,
CA) and visualized through chemiluminescence using the
Supersignal West Pico Chemiluminescent Substrate (Pierce,
Thermo Scientific, Rockford).
2.5. Statistical Analysis. Statistical analyses of the gene
expression and methylation assays were performed by non-
parametric one-way ANOVA, succeeded by Tukey’s post hoc
test, using the GraphPad Prism 5.0 program. At least two
independent replicates were performed for each analysis. In
all figures, the error bars in the histograms represent themean
standard error of the obtained results.
3. Results and Discussion
In a previous study, using a murine melanoma model
obtained through sequential anchorage blockade cycles
in melan-a melanocytes, Molognoni and coworkers [27]
demonstrated alterations in the expression of genes involved
in the epigenetic machinery and changes in DNA methy-
lation levels in premalignant melanocytes, suggesting that
epigenetic reprogramming occurs prior to malignant trans-
formation in these cells. To verify the contribution ofmiRNAs
to this phenomenon, the expression of key components of
the epigenetic machinery was evaluated in parental, melan-
a, and melan-a-derived melanoma cells (the nonmetastatic
4C3− cell line and its metastatic derivative, 4C3+). These
4C3 cells have been characterized elsewhere [26, 36]. To
verify whether the 4C3− and 4C3+ melanoma cell lines
exhibit an altered pattern of DNA methylation, methylation
of repetitive DNA sequences (retrovirus-C and intracisternal
A particle elements) was assessed using the Ms-SNuPE
method. The metastatic 4C3+ cell line showed a significant
reduction of global methylation compared with melan-a and
nonmetastatic 4C3− cells (Figure 1). This result is consistent
with the global demethylation observed in most tumor types
[2, 37] and in other melanoma cells in the same murine
melanoma model [27]. Hence, the expression of Dnmt3a,
Dnmt3b,Mecp2, and Ezh2 (Figure 2) of the parental melan-a
and melanoma 4C3− and 4C3+ cell lines was assessed at the
protein level. Dnmt3b expression was reduced in 4C3− cells
compared to normal melanocytes melan-a and even more
reduced in 4C3+ metastatic cells (Figure 2(b)). The same
patternwas seen inDnmt3a andMecp2, however, in an atten-
uated manner (Figures 2(a) and 2(c)). Taken together, these
results show that the global DNA hypomethylation observed
during the progression of melanoma is accompanied by
downregulation of Dnmt3a, Dnmt3b, and Mecp2 expression.
Whether DNMT3a and DNMT3b are downregulated during
cancer development is a debated issue. Indeed, most tumor
types overexpress DNMTs [38]. However, there is evidence
that DNMTs are mutated or weakly expressed in cancer cells
[39–41]. Our findings are consistent with those of Molognoni
et al. [27], who also observed Mecp2 downregulation during
malignant transformation.However, these authors found that
the expression of Dnmt3b was not statistically significantly
different betweenmelan-a, premalignant, nonmetastatic, and
metastatic melanoma cells and Dnmt3a was upregulated in
the metastatic cell line, possibly reflecting clonal differences.
Additionally, we have assessed the expression of Ezh2 at
the protein level (Figure 2(d)) in all 3 studied cell lines. In
melan-a and in 4C3+, Ezh2 was found poorly expressed but
overexpressed in 4C3−. Accordingly, this expression fluctu-
ation was also seen in Molognoni et al. [27], showing that
Ezh2 might be involved in the primary events of melanocytes
transformation.
Recently, it has been reported that numerous miRNAs
are involved in the silencing of components of the epige-
netic machinery (reviewed in [42]). Moreover, it is been
predicted that some miRNAs are involved in the regulation
of genes related to the same pathway [43]. Indeed, the miR-
29 family is particularly interesting, as overexpression of its
members in lung tumor cells significantly reduces Dnmt3a
and Dnmt3b expression [30]. More specifically, miR-29b
reduces DNMT1, DNMT3A, and DNMT3B expression in






































Figure 1: Metastatic melanoma cells are hypomethylated compared with nontumorigenic melan-a cells. The methylation status of three
specific CpGs associated with A-repeats (a) and two CpGs in the retrovirus-C repetitive sequence (b) were evaluated using Ms-SNuPE in
the melan-a, 4C3−, and 4C3+ cell lines. The percentage of methylation was determined by calculating the average at the different CpG sites
analyzed. Ma: nontumorigenic melan-a melanocyte line; 4C3−: nonmetastatic melanoma cell line; 4C3+: metastatic melanoma cell line.
∗
𝑝 < 0.05.
acutemyeloid leukemia (AML) [44] and germ cells [45].miR-
29b and miR-29c also target YY1, a chromatin remodeling
protein that recruits PRC2 and a histone deacetylase, HDCA,
to suppress the expression of specific loci [46]. miR-26
is also associated with the downregulation of DNMT3B,
since transfection of miR-26b in human breast cancer cells
showed diminished expression of DNMT3B. On the other
hand, transfection of miR-26b antagomiR showed an over-
expression of DNMT3B [32]. miR-26a also targets Ezh2
mRNA [31], and both members of miR-26 family (miR-
26a and miR-26b) could target Mecp2/MECP2 mRNA, as
predicted by several miRNA target prediction programs
(Microrna.org; TargetScan 4.2; Pictar; andDIANA/miRGen).
Moreover, miR-203 has been validated as a regulator of Bmi-
1, which is a member of the Polycomb repressive complex 1
(PRC1) family of proteins and is also involved in epigenetic
modifications [47]. Additionally, the expression of miR-203
has been inversed correlated to DNMT3B in breast cancer
cells [32, 33]. This miRNA might also target Mecp2/MECP2,
as predicted using the same four prediction programs. Thus,
thesemiRNAs are good candidates for the regulation of genes
involved in the epigenetic machinery during melanocyte
transformation.
Since miR-29 family was validated to target Dnmt3a and
Dnmt3b [30], the expression profile of the miR-29 family was
evaluated and showed that miR-29a did not contribute to the
phenotype of themalignant cells, as there were no statistically
significant differences observed between the 3 studied cell
lines (Figure 3(a)). Nevertheless, miR-29b and miR-29c were
significantly upregulated in 4C3+ and 4C3− cells, respec-
tively, compared with melan-a cells (Figures 3(b) and 3(c),
resp.). SinceDnmt3a andDnmt3b are downregulated in 4C3−
and in 4C3+ cells (Figures 2(a) and 2(b)), it is conceivable that
these miRNAs regulate the de novoDnmts expression during
melanocyte transformation.
The expression of miR-26a was also assessed, showing a
significant reduction in its expression in 4C3− cells compared
with parental cells. However, upregulation was observed
in metastatic melanoma cells compared with melan-a and
4C3− cells (Figure 4(a)). The observed pattern of miR-
26a expression is opposed to its validated target Ezh2
(Figure 2(d)). Since the latter is upregulated in nonmetastatic
cells compared with melanocytes and metastatic melanoma
cells, it is suggestive that miR-26a might regulate Ezh2
expression during the melanocytes malignant transforma-
tion.This histone methyltransferase is a part of the Polycomb
Complex Repressor 2 (PCR2) system, which represses gene
expression through interactions with unmethylated CpG
islands in normal cells (reviewed in [48]). Ezh2 has been
associated with the aberrant silencing of CpG islands near
the promoters of tumor suppressor genes [49]. This site-
specific hypermethylation could result from the interaction
of Ezh2 with Dnmts to position these proteins near CpG
islands, promoting de novo methylation (reviewed in [48]).
The overexpression of Ezh2 during cell transformation [50]
might promote the assembly of Dnmts to the CpG islands
providing a more stable silencing mark. Since overexpression
of Dnmts is not obligatory to promote aberrant hyperme-
thylation in CpG island in cancer cells [41], low levels of
these proteins might be sufficient to silence CpG islands near
suppressor gene promoters that are more susceptible to DNA
methyltransferases in the presence of abundant Ezh2 [51].
Conversely, downregulation of Dnmt3a, Dnmt3b, andMecp2
could favor the derepression of repetitive DNA and the global
demethylation observed in tumor cells, promoting genomic
instability. Thus, overexpression of the epigenetic machinery
might not be necessary to maintain the transformed state.
Further, the upregulation of miR-26a seen in 4C3+ cells
and miR-26b seen in 4C3− and 4C3+ cells (Figures 4(a) and
4(b)) is opposed toMecp2 expression in these cells compared






















Figure 2: Dnmt3a (a), Dnmt3b (b), Mecp2 (c), and Ezh2 (d) expression profile in melan-a, 4C3−, and 4C3+ before and after treatment with
5-aza-CdR. The protein expression was evaluated by Western blotting in melan-a, 4C3−, and 4C3+ cells that were untreated or treated with
10𝜇M 5-aza-CdR for 48 hours.The expression of 𝛽-actin was used for normalization. melan-a: nontumorigenic melan-a melanocyte lineage;
4C3−: nonmetastatic melanoma cell line; and 4C3+: metastatic melanoma cell line.





















































































































































Figure 3: miR-29 expression during melanocyte transformation and 5-aza-CdR treatment. miR-29a (a), miR-29b (b), and miR-29c (c)
expression was evaluated in the three cell lines via qRT-PCR. The cells were treated with 10𝜇M 5-aza-CdR for 48 hours, and the expression
of miR-29a (d), miR-29b (e), and miR-29c (f) was subsequently evaluated. U6 was used for normalization. Ma: nontumorigenic melan-a
melanocyte lineage; 4C3−: nonmetastatic melanoma cell line; and 4C3+: metastatic melanoma cell line. ∗𝑝 < 0.05; ∗∗∗𝑝 < 0.001.











































































































Figure 4: miR-26 expression during melanocyte transformation and 5-aza-CdR treatment. miR-26a (a) and miR-26b (b) expression was
examined in the three cell lines using qRT-PCR. The cells were treated with 10𝜇M 5-aza-CdR for 48 hours, and the expression of miR-26a
(c) and miR-26b (d) was subsequently evaluated. U6 was used for normalization. Ma: nontumorigenic melan-a melanocyte lineage; 4C3−:
nonmetastatic melanoma cell line; and 4C3+: metastatic melanoma cell line. ∗𝑝 < 0.05; ∗∗𝑝 < 0.01; ∗∗∗𝑝 < 0.001.
with melan-a cells (Figure 2(c)). Because the miR-26 family
has been predicted to target Mecp2/MECP2 mRNAs, these
miRNAs might be relevant to Mecp2 downregulation and
are good candidates to further validation as its regulators.
Finally, miR-26b and DNMT3b showed an inverse corre-
lation expression, whereas DNMT3b is downregulated and
miR-26b is upregulated in melanoma cells compared to
melanocytes, which corroborates to previous evidence that
DNMT3b is regulated by miR-26b [32].
The analysis of the expression of othermiRNA that poten-
tially targets Mecp2 and Dnmt3b, miR-203, revealed that it
was significantly upregulated in 4C3− cells compared with
the melan-a and 4C3+ cell lines (Figure 5(a)). This finding
supports the hypothesis that miR-203 regulates both genes
and might be involved in the induction of the transformed
state as only the nonmetastatic cell line showed an upregula-
tion of miR-203 expression. Alternatively, miR-203 could be
overexpressed in 4C3− cells as a feedbackmechanism to avoid
transformation, as miR-203 has been previously described as
an antimetastatic agent in human prostate cancer [52].
To test the hypothesis that miR-203 targets Dnmt3b, we
overexpress themiR-203 inmelan-a cells. A significant down-
regulation ofDnmt3b at RNAandprotein levels was observed
(Figure 6), being the first evidence of miR-203 regulating
Dnmt3b.
To verify whether these miRNAs could be epigenetically
regulated, each cell line was treated with 5-aza-CdR. After
treatment, increased miR-203 expression was observed in
melan-a and 4C3− cells (Figure 5(b)). These results are
consistent with the literature reporting that miR-203 is
epigenetically silenced in human tumor cells [53, 54]. miR-26
andmiR-29 familymemberswere also overexpressed in 4C3−
cells compared with untreated cells (Figures 4(c), 4(d), 3(d),
3(e), and 3(f), resp.). Given that miR-26 and miR-29 exhibit
expression patterns similar to that of miR-203 in 4C3− cells
treated with 5-aza-CdR, it is conceivable that these miRNAs
are also epigenetically regulated in these cells.The expression
of these miRNAs was not statistically significantly different
in treated metastatic 4C3+ cells compared with untreated
4C3+ cells, possibly because the untreated counterpart
cells are already demethylated. An in silico analysis of
CpG islands near the miRNA genes of Mus musculus and
their promoters was performed using Genome Browser
(http://genome.ucsc.edu/cgi-bin/hgGateway) and the Tran-
scriptional Regulatory Element Database (http://rulai.cshl
.edu/cgi-bin/TRED/tred.cgi?process=home). The analysis





















































Figure 5: miR-203 expression during melanocyte transformation and 5-aza-CdR treatment. miR-203 (a) expression was evaluated in the
three cell lines using qRT-PCR. The cells were treated with 10𝜇M 5-aza-CdR for 48 hours, and the expression of miR-203 (b) was then
evaluated. U6 was used for normalization. Ma: nontumorigenic melan-a melanocyte lineage; 4C3−: nonmetastatic melanoma cell line; and

















































Figure 6: Dnmt3b expression after exogenous overexpression of miR-203 in melan-a cells. (a) miR-203 and (b) Dnmt3b expression was
evaluated by qRT-PCR in melan-a cells transfected with pSilencer-mmu-miR-203 or pSilencer-Scrambled. The expression of Dnmt3b at
protein level (c) was also evaluated after the same treatment by Western blotting. ∗𝑝 < 0.05.
showed that miR-26a-1 is hosted within a gene, whose
promoter overlaps with a CpG island of 1230 bp. The
intragenic miRNAs, miR-26a-2 (miR-26a-2 and miR-546)
cluster and miR-26b, are both associated with CpG islands
of 1752 and 1098 bp near the transcription start site (TSS)
in the host gene or overlapping with the predicted host
gene promoter, respectively. The miR-29a/29b-1 cluster is
intergenic and exhibits 4 small CpG islands near the TSS,
ranging from 206 to 836 bp. It has been predicted that this
cluster is imprinted, as it is embedded into the imprinted
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Copg 2 cluster [55]. The only exception to this pattern is the
intragenic miR-29b-2/29c cluster, which presents a 558 bp
CpG island distant from its TSS. miR-203, by its turn, is
intergenic and seems to be embedded in a CpG island of
804 bp. These analyses showed that all miRNAs studied here
are near of regions commonly regulated epigenetically.
To our knowledge, this study provides the first evidence
that miR-26a, miR-26b, miR-29b, and miR-29c might be
epigenetically regulated in mouse and is in agreement with
study of Desjobert and colleagues that showed miR-29a
methylated in human lymphoma cells [56]. An estimated
60% of human coding genes have been associated with
CpG islands, while approximately half of known miRNA
genes are located near or embedded within a CpG island,
indicating that methylation is an important mechanism
for the regulation of miRNA transcription [57]. However,
upregulation of miRNAs following 5-aza-CdR treatment was
observed only in the nonmetastatic melanoma cell line,
potentially reflecting the unstable epigenetic marks in these
cells. The expression of Dnmt3b was assessed from total
protein extracts, demonstrating the efficiency of 5-aza-CdR
treatment in inducing Dnmt3b degradation (Figure 2(b)). In
contrast, no differences in Mecp2 expression were observed
at the protein (Figure 2(c)) following 5-aza-CdR treatment
compared with untreated cells. Taken together, these findings
support the idea that these miRNAs are epigenetically regu-
lated. Nevertheless, they must be further characterized.
In conclusion, this study demonstrated that miR-203
overexpression promotes Dnmt3b downregulation. Addi-
tionally, it highlights the importance of miR-26, miR-29, and
miR-203 in promoting the imbalanced expression of genes
involved in the epigenetic machinery during the malignant
transformation of melanocytes. These results indicate that
the miRNA methylation status plays an important role in
the establishment of the altered epigenetic state observed in
tumors.
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